Literature DB >> 22504293

A pilot comparison of 18F-fluorodeoxyglucose and 18F-fluorocholine PET/CT to predict early recurrence of unifocal hepatocellular carcinoma after surgical resection.

Laetitia Fartoux1, Sona Balogova, Valérie Nataf, Khaldoun Kerrou, Virginie Huchet, Olivier Rosmorduc, Jean-Noël Talbot.   

Abstract

OBJECTIVE: Presurgical identification of patients at high risk for early recurrence of hepatocellular carcinoma (HCC) after resection could warrant additional therapies. F-fluorodeoxyglucose (FDG) uptake by the tumour on preoperative PET can predict HCC recurrence after resection as effectively as poor differentiation or presence of microvascular invasion (MVI) on postsurgical histology. A better sensitivity for the detection of HCC nodules has been reported with F-fluorocholine (FCH), a PET tracer of lipid metabolism. This pilot study aimed to compare preoperative FDG and FCH PET/CT for predicting early recurrence of unifocal HCC, occurring within 6 months after surgical resection.
METHODS: FDG and FCH tumour uptakes were assessed on preoperative PET/CT by two masked readers. On FCH PET/CT, a photopenic lesion and a hot focus were considered as indicative of malignancy. During postoperative follow-up, recurrence was searched for by regularly performing CT and MRI.
RESULTS: In 11 consecutive HCC patients, the detection rate was greater with FCH (80%) than with FDG (27%). After resection, the overall recurrence rate was 55%. Early recurrence occurred in four patients, who were the only ones with an FDG-positive and FCH-photopenic tumour, with a significant reduction in disease-free survival. On postsurgical histology, those four patients also presented with MVI and satellite nodules. Histological differentiation and capsule disruption appeared less accurate than PET/CT or MVI in predicting early recurrence.
CONCLUSION: In unifocal HCC, the FCH photopenic pattern was associated with MVI and predicted early HCC recurrence after surgical resection as accurately as did an FDG uptake. Larger studies with FCH are warranted.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22504293     DOI: 10.1097/MNM.0b013e328350fb9f

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  10 in total

1.  Transcriptomics Associates Molecular Features with 18F-Fluorocholine PET/CT Imaging Phenotype and Its Potential Relationship to Survival in Hepatocellular Carcinoma.

Authors:  Sandi A Kwee; Maarit Tiirikainen; Miles M Sato; Jared D Acoba; Runmin Wei; Wei Jia; Loic Le Marchand; Linda L Wong
Journal:  Cancer Res       Date:  2019-02-13       Impact factor: 12.701

2.  Volumetric parameters on FDG PET can predict early intrahepatic recurrence-free survival in patients with hepatocellular carcinoma after curative surgical resection.

Authors:  Jeong Won Lee; Sang Hyun Hwang; Hyun Jeong Kim; Dongwoo Kim; Arthur Cho; Mijin Yun
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-07-11       Impact factor: 9.236

3.  Diagnostic role of radiolabelled choline PET or PET/CT in hepatocellular carcinoma: a systematic review and meta-analysis.

Authors:  Francesco Bertagna; Mattia Bertoli; Giovanni Bosio; Giorgio Biasiotto; Ramin Sadeghi; Raffaele Giubbini; Giorgio Treglia
Journal:  Hepatol Int       Date:  2014-09-03       Impact factor: 6.047

4.  Diagnostic value of combining ¹¹C-choline and ¹⁸F-FDG PET/CT in hepatocellular carcinoma.

Authors:  Maria-Angéla Castilla-Lièvre; Dominique Franco; Philippe Gervais; Bertrand Kuhnast; Hélène Agostini; Lysiane Marthey; Serge Désarnaud; Badia-Ourkia Helal
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-11-18       Impact factor: 9.236

5.  Nuclear imaging for functional evaluation and theragnosis in liver malignancy and transplantation.

Authors:  Jae Seon Eo; Jin Chul Paeng; Dong Soo Lee
Journal:  World J Gastroenterol       Date:  2014-05-14       Impact factor: 5.742

6.  Does 18F-FDG positron emission tomography-computed tomography have a role in initial staging of hepatocellular carcinoma?

Authors:  Yuri Cho; Dong Hyeon Lee; Yun Bin Lee; Minjong Lee; Jeong-Ju Yoo; Won-Mook Choi; Young Youn Cho; Jin Chul Paeng; Keon Wook Kang; June-Key Chung; Su Jong Yu; Jeong-Hoon Lee; Jung-Hwan Yoon; Hyo-Suk Lee; Yoon Jun Kim
Journal:  PLoS One       Date:  2014-08-25       Impact factor: 3.240

7.  The value of [11C]-acetate PET and [18F]-FDG PET in hepatocellular carcinoma before and after treatment with transarterial chemoembolization and bevacizumab.

Authors:  Shuren Li; Markus Peck-Radosavljevic; Philipp Ubl; Wolfgang Wadsak; Markus Mitterhauser; Eva Rainer; Matthias Pinter; Hao Wang; Christian Nanoff; Klaus Kaczirek; Alexander Haug; Marcus Hacker
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-05-29       Impact factor: 9.236

8.  Metabolism-Associated Gene Signatures for FDG Avidity on PET/CT and Prognostic Validation in Hepatocellular Carcinoma.

Authors:  Hyunjong Lee; Joon Young Choi; Je-Gun Joung; Jae-Won Joh; Jong Man Kim; Seung Hyup Hyun
Journal:  Front Oncol       Date:  2022-01-31       Impact factor: 6.244

Review 9.  18F-FDG /18F-Choline Dual-Tracer PET Behavior and Tumor Differentiation in HepatoCellular Carcinoma. A Systematic Review.

Authors:  Jérôme Ghidaglia; Nicolas Golse; Alina Pascale; Mylène Sebagh; Florent L Besson
Journal:  Front Med (Lausanne)       Date:  2022-07-07

10.  Differential Diagnosis of Hepatic Mass with Central Scar: Focal Nodular Hyperplasia Mimicking Fibrolamellar Hepatocellular Carcinoma.

Authors:  Teodoro Rudolphi-Solero; Eva María Triviño-Ibáñez; Antonio Medina-Benítez; Javier Fernández-Fernández; Daniel José Rivas-Navas; Alejandro José Pérez-Alonso; Manuel Gómez-Río; Tarik Aroui-Luquin; Antonio Rodríguez-Fernández
Journal:  Diagnostics (Basel)       Date:  2021-12-27
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.